title: [Progression and challenge of anti-vascular endothelial growth factor therapy in retinal neovascular disease].
abstract: Anti-vascular endothelial growth factor (VEGF) therapy as an effective therapeutic method has been a standard treatment strategy in retinal neovascular disease, contributing to restore vision and reduce the prevalence of blindness. With the research on the pathogenesis of retinal neovascular disease and implementation of clinical trials, anti-VEGF therapy is continuously optimized. Meanwhile, the complications after the use of anti-angiogenetic drugs are exposed. The present article summarizes the update and challenge of anti-VEGF therapy in retinal neovascular disease.
authors.affiliation: Department of Ophthalmology, Peking University People's Hospital; Key Laboratory of Vision Loss and Restoration (Peking University), Ministry of Education; Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, Beijing 100044, China.
authors.forename: Xiaoxin
authors.initials: X
authors.lastname: Li
authors.forename: Yujing
authors.initials: Y
authors.lastname: Bai
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D015861:Retinal Neovascularization / Q000188:drug therapy*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
chemical_list: D020533:Angiogenesis Inhibitors; D042461:Vascular Endothelial Growth Factor A